NasdaqGS - Nasdaq Real Time Price USD

Neurocrine Biosciences, Inc. (NBIX)

121.61
+2.69
+(2.26%)
At close: May 7 at 4:00:01 PM EDT
118.69
-2.92
(-2.40%)
Pre-Market: 9:00:18 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,412,600
2,355,300
1,887,100
1,488,700
1,133,500
Cost of Revenue
35,700
34,000
39,700
23,200
14,300
Gross Profit
2,376,900
2,321,300
1,847,400
1,465,500
1,119,200
Operating Expense
1,875,500
1,738,300
1,452,600
1,216,500
911,400
Operating Income
501,400
583,000
394,800
249,000
207,800
Net Non Operating Interest Income Expense
--
-35,600
52,800
4,100
-25,800
Other Income Expense
400
-61,400
-115,500
-39,200
-80,600
Pretax Income
466,200
486,000
332,100
213,900
101,400
Tax Provision
160,400
144,700
82,400
59,400
11,800
Net Income Common Stockholders
305,800
341,300
249,700
154,500
89,600
Diluted NI Available to Com Stockholders
305,800
341,300
249,700
154,500
89,600
Basic EPS
3.05
3.40
2.56
1.61
0.95
Diluted EPS
2.95
3.29
2.47
1.56
0.92
Basic Average Shares
100,375
100,400
97,700
95,800
94,600
Diluted Average Shares
103,425
103,700
101,000
98,900
97,900
Total Operating Income as Reported
494,800
570,500
250,900
249,000
102,500
Total Expenses
1,911,200
1,772,300
1,492,300
1,239,700
925,700
Net Income from Continuing & Discontinued Operation
305,800
341,300
249,700
154,500
89,600
Normalized Income
363,719.65
384,418.97
336,542.37
182,814.17
160,820.51
Interest Income
--
91,000
52,800
4,100
--
Interest Expense
--
126,600
4,600
7,100
25,800
Net Interest Income
--
-35,600
52,800
4,100
-25,800
EBIT
531,000
612,600
394,800
249,000
127,200
EBITDA
559,500
639,700
416,100
264,600
138,100
Reconciled Cost of Revenue
35,700
34,000
39,700
23,200
14,300
Reconciled Depreciation
28,500
27,100
21,300
15,600
10,900
Net Income from Continuing Operation Net Minority Interest
305,800
341,300
249,700
154,500
89,600
Total Unusual Items Excluding Goodwill
-88,300
-61,400
-115,500
-39,200
-80,600
Total Unusual Items
-88,300
-61,400
-115,500
-39,200
-80,600
Normalized EBITDA
647,800
701,100
531,600
303,800
218,700
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-30,380.35
-18,281.03
-28,657.63
-10,885.83
-9,379.49
12/31/2021 - 5/23/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BCRX BioCryst Pharmaceuticals, Inc.
10.08
-1.85%
 
LNTH Lantheus Holdings, Inc.
80.49
-23.23%
 
RGC Regencell Bioscience Holdings Limited
189.99
+25.82%
 
ELAN Elanco Animal Health Incorporated
12.01
+26.29%
 
ALKS Alkermes plc
30.38
+0.07%
 
UTHR United Therapeutics Corporation
306.92
+4.03%
 
ZTS Zoetis Inc.
155.99
+4.08%
 
SXTC China SXT Pharmaceuticals, Inc.
1.9000
-7.32%
 
TEVA Teva Pharmaceutical Industries Limited
17.60
+9.18%
 
AVDL Avadel Pharmaceuticals plc
9.47
+9.61%